Nutra Pharma Corp Common Stock USD0.001
Nutra Pharma Corp. is a biopharmaceutical company. The Company is engaged in the acquisition, licensing and commercialization of pharmaceutical products and technologies, as well as homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, autoimmune and infectious diseases. The Company's subsidiary and drug discovery arm, ReceptoPharm, Inc. (ReceptoPharm), carries its homeopathic and drug discovery research and clinical development and has developed homeopathic drugs for the treatment of pain: Cobroxin, an over-the-counter pain reliever designed to treat moderate to severe (Stage II) chronic pain; Nyloxin and Nyloxin Extra Strength, stronger versions of Cobroxin, and Pet Pain-Away, an over-the-counter pain reliever designed to treat pain in cats and dogs. It has developed two drug candidates: RPI-78M, to treat neurological diseases and autoimmune diseases, and RPI-MN, to treat viral diseases.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.